Healio
›
Hematology/Oncology
›
Hematologic Malignancies
›
News
-
Meeting News Coverage
Perspective
-
-
HemOnc Today, January 25, 2013
-
ATLANTA — The addition of the investigational oral proteasome inhibitor MLN9708 to standard multiple myeloma therapy increases the efficacy of...More
»
-
Meeting News Coverage
Video
-
-
December 10, 2012
-
ATLANTA — Claire E. Dearden, MD, consultant hematologist and head of the CLL Clinic at Royal Marsden Hospital in London, discusses encouraging...More
»
-
Meeting News Coverage
Perspective
-
-
HemOnc Today, January 25, 2013
-
ATLANTA — The administration of the histone deacetylase inhibitor vorinostat in matched related donor reduced-intensity conditioning allogeneic...More
»
-
Meeting News Coverage
-
-
HemOnc Today, January 25, 2013
-
ATLANTA — The novel oral tyrosine kinase inhibitor ponatinib produced durable response among patients with chronic myeloid leukemia and Philadelphia...More
»
-
Meeting News Coverage
-
-
HemOnc Today, January 25, 2013
-
ATLANTA — Hematopoietic stem cell transplants with double units of transfused umbilical cord blood offered no survival advantage over...More
»
-
Meeting News Coverage
-
-
HemOnc Today, January 25, 2013
-
ATLANTA — Patients with variation in the MRP2, RAC2 and HFE genes had up to a threefold higher risk of developing heart failure following...More
»
-
Meeting News Coverage
Perspective
-
-
HemOnc Today, January 25, 2013
-
ATLANTA —The omission of the anthracycline daunorubicin during induction treatment of childhood standard-risk B-cell acute lymphocytic leukemia did...More
»
-
Meeting News Coverage
-
-
HemOnc Today, January 10, 2013
-
ATLANTA — Patients with newly diagnosed non-high–risk acute promyelocytic leukemia who underwent a front-line combination of arsenic trioxide...More
»
-
Meeting News Coverage
-
-
HemOnc Today, December 25, 2012
-
The presence of a genetic biomarker known as Wilms’ tumor single nucleotide polymorphism rs16754 may reduce toxicity from chemotherapy in...More
»
-
Meeting News Coverage
Perspective
-
-
December 8, 2012
-
ATLANTA — The combination of ibrutinib and rituximab produced favorable overall response rates among high-risk patients with chronic lymphocytic...More
»